变应性鼻炎的长期抗炎治疗

doi:10.6040/j.issn.1673-3770.0.2017.184

摘要/Abstract

摘要： 已经证实许多没有症状的变应性鼻炎(AR)患者存在亚临床的炎症状态,接触阈值以下的变应原剂量能够引起鼻黏膜炎性细胞的浸润,包括细胞黏附分子、鼻腔和结膜嗜酸性粒细胞以及其他炎性标记物的表达显著增加,这些都不会导致明显的过敏症状。虽然治疗AR通常以缓解症状为主,减轻无症状时期的炎性反应可能会对AR发病、进展以及严重程度有积极的影响。因此制定治疗方案时应该充分考虑到对于症状缓解后仍存在的潜在炎性反应。目前主要有三类治疗AR的药物,包括抗组胺药、抗白三烯药和鼻内糖皮质激素,鼻内糖皮质激素对AR患者持续炎症的长期抑制可能是最合理的治疗选择。

关键词: 变应性鼻炎, 糖皮质激素, 抗过敏药物, 药物治疗, 炎症

Abstract: In Symptom-free patients with allergies, a subclinical inflammatory state has been described, in which subthreshold doses of an allergen have been found to cause inflammatory cell infiltration into the nasal mucosa. This includes increases in the levels of cellular adhesion molecules, nasal and conjunctival eosinophilia, and other markers of inflammation, which do not result in overt allergic symptoms. While allergic rhinitis(AR)treatment is typically guided by the need to reduce symptoms, the treatment strategies that reduce inflammation during asymptomatic periods may have positive effects on the onset, progression, and severity of AR. Therefore, treatment options that target underlying inflammation along with symptom relief should be considered. There are three major classes of commonly used AR medications, namely, intranasal corticosteroids, antihistamines, and antileukotrienes. Among these, intranasal corticosteroids appear to be the most reasonable therapeutic option in patients who would benefit from continuous inhibition of persistent inflammation.

Key words: Allergic rhinitis, Glucocorticoids, Inflammation, Anti-allergic agents, Drug therapy

中图分类号:

R765.21

史丽,赵莉,张红萍. 变应性鼻炎的长期抗炎治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 9-12.

SHI Li, ZHAO Li, ZHANG Hongping. Long-term anti-inflammatory treatment of allergic rhinitis.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 9-12.

参考文献

[1] Bousquet J, Schunemann HJ, Samolinski B, et al. Allergic Rhinitis and its Impact on Asthma(ARIA): achievements in 10 years and future needs[J]. J Allergy Clin Immunol, 2012, 130(5):1049-1062.
[2] Brozek JL, Baena-Cagnani CE, Bonini S, et al. Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update[J]. Allergy, 2008, 63(1):38-46.
[3] Assing K, Bodtger U, Poulsen LK, et al. Grass pollen symptoms interfere with the recollection of birch pollen symptoms-a prospective study of suspected, asymptomatic skin sensitization[J]. Allergy, 2007, 62(4):373-377.
[4] Montoro J, Sastre J, Jauregui I, et al. Allergic rhinitis: continuous or on demand antihistamine therapy?[J]. J Invest Allergy Clin Immunol, 2007,17(Suppl 2):21-27.
[5] Pitsios C, Papadopoulos D, Kompoti E, et al. Efficacy and safety of mometasonefuroatevsnedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2006, 96(5):673-678.
[6] Ricca V, Landi M, Ferrero P, et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis[J]. J Allergy Clin Immunol, 2000, 105(1 Pt 1):54-57.
[7] Salmun LM. Antihistamines in late-phase clinical development for allergic disease[J]. Expert Opin Invest Drugs, 2002, 11(2):259-273.
[8] Canonica GW, Tarantini F, Compalati E, et al. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials[J]. Allergy, 2007, 62(4):359-366.
[9] Pasquali M, Baiardini I, Rogkakou A, et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters[J]. Clin Exp Allergy, 2006, 36(9):1161-1167.
[10] Lauriello M, Muzi P, Di Rienzo L, et al. A two-year course of specific immunotherapy or of continuous antihistamine treatment reverse eosinophilic inflammation in severe persistent allergic rhinitis[J]. Acta Otorhinolaryngol Ital, 2005, 25(5):284-291.
[11] Dizdar EA, Sekerel BE, Keskin O, et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2007, 71(6):843-849.
[12] Canonica GW, Fumagalli F, Guerra L, et al. Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study[J]. Curr Med Res Opin, 2008, 24(10):2829-2839.
[13] Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group(IPCRG)Guidelines: management of allergic rhinitis[J]. Prim Care Respir J, 2006, 15(1):58-70.
[14] von Moltke J, Trinidad NJ, Moayeri M, et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo[J]. Nature, 2012, 490(7418):107-111.
[15] Montoro J, Del Cuvillo A, Mullol J, et al. Validation of the modified allergic rhinitis and its impact on asthma(ARIA)severity classification in allergic rhinitis children: the PEDRIAL study[J]. Allergy, 2012, 67(11):1437-1442.
[16] Xu Y, Zhang J, Wang J. The efficacy and safety of selective H1-antihistamine versus leukotriene receptor antagonist for seasonal allergic rhinitis: a meta-analysis[J]. PLoS One, 2014, 9(11):e112815.
[17] Ciprandi G, Frati F, Marcucci F, et al. Nasal cytokine modulation by montelukast in allergic children: a pilot study[J]. Eur Ann Allergy Clin Immunol, 2003, 35(8):295-299.
[18] Wei C. The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: A systematic review and meta-analysis[J]. Biomed Pharmacother, 2016, 83:989-997.
[19] Erdogan BA, Sanli A, Paksoy M, et al. Quality of life in patients with persistent allergic rhinitis treated with desloratadinemonotherapy or desloratadine plus montelucast combination[J]. Kulak Burun Bogaz Ihtis Derg, 2014, 24(4):217-224.
[20] Yilmaz O, Altintas D, Rondon C, et al. Effectiveness of montelukast in pediatric patients with allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2013, 77(12):1922-1924.
[21] Mygind N, Nielsen LP, Hoffmann HJ, et al. Mode of action of intranasal corticosteroids[J]. J Allergy Clin Immunol, 2001, 108(Suppl 1):S16-25.
[22] Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis[J]. Ann Allergy Asthma Immunol, 2002, 89(5):479-484.
[23] Ciprandi G, Tosca MA, Passalacqua G, et al. Intranasal mometasonefuroate reduces late-phase inflammation after allergen challenge[J]. Ann Allergy Asthma Immunol, 2001, 86(4):433-438.
[24] Baroody FM, Shenaq D, DeTineo M, et al. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms[J]. J Allergy Clin Immunol, 2009, 123(6):1342-1348.
[25] Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents[J]. Allergy Asthma Proc, 2007, 28(2):216-225.
[26] Corren J, Manning BE, Thompson SF, et al. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study[J]. J Allergy Clin Immunol, 2004, 113(3):415-419.
[27] Graft D, Aaronson D, Chervinsky P, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasonefuroate aqueous nasal spray[J]. J Allergy Clin Immunol, 1996, 98(4):724-731.
[28] Canonica GW, Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies[J]. Clin Exp Immunol, 2009, 158(3):260-271.
[29] Berger WE, Meltzer EO. Intranasal spray medications for maintenance therapy of allergic rhinitis[J]. Am J Rhinol Allergy, 2015, 29(4):273-282.

相关文章 15

[1]	李梦欣,徐慧,张晓玲,薛晴,纪霜钰,李莹莹,崔丽梅,郭兆剑,宋西成,孙岩,陈良. 糖皮质激素通过下调水通道蛋白2缓解精氨酸加压素诱导的膜迷路积水[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 1-6.
[2]	李凯,罗丹. 润目灵方激活LC3-ATG5自噬通路抑制炎症因子表达改善干眼大鼠眼表损伤的机制[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 92-101.
[3]	辛敏,王少明. 炎症与感染性嗅觉功能障碍的神经免疫机制及治疗策略[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 111-124.
[4]	吕倩,唐源,顾子君,施赛磊,刘萍,万文锦. 变应性鼻炎患者疾病获益感现状及影响因素分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 21-28.
[5]	顾敏,陆美萍. 纳米药物输送系统在变应性鼻炎过敏原免疫治疗中的应用进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 106-111.
[6]	段思妤,薛金梅. 组蛋白去乙酰化酶2在慢性气道炎症性疾病糖皮质激素抵抗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 120-126.
[7]	秦娜娜,李玉芬,孙雨浩,魏健,李钦. 基于TGF-β1/Smad信号通路探讨白细胞介素13受体α2对变应性鼻炎大鼠鼻黏膜组织重塑的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 71-77.
[8]	熊琴, 张砚, 乌日娜, 李锋, 唐力行. 鼻用糖皮质激素在儿童中的应用[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 160-167.
[9]	许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33.
[10]	刘怡君,谷悦,官大宇,杨玉成,沈暘. 翼管神经切断术在难治性变应性鼻炎中远期临床疗效和安全性[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 42-48.
[11]	张婷,王美兰,高映勤. 白细胞介素35在变应性鼻炎中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 139-147.
[12]	李莉琳,李馨仪,关建. 阻塞性睡眠呼吸暂停与抑郁症共病机制的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 89-96.
[13]	张竹萍,彭孜灿,肖振龙,李程,喻迪,王兴龙,陈伟,郭蓓. 新型鼻分泌物嗜酸粒细胞阳离子蛋白-髓过氧化物酶试纸在变应性鼻炎中的应用价值[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 129-134.
[14]	毛一恒,冯洁,何润田. 高血脂对视网膜损害与脉络膜厚度关系研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 162-167.
[15]	曹正勇,李小波. 慢性鼻-鼻窦炎合并哮喘术后短程局部使用糖皮质激素辅助治疗的安全性和有效性[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 43-50.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed